Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts

Journal of Cardiovascular Pharmacology

Volumn 36, Issue 2, 2000, Pages 248-254

  Mital, Seema ^a   Magneson, Amy ^b   Loke, Kit E ^b   Liao, James ^c   Forfia, Paul R ^b   Hintze, Thomas H ^b  

^a Columbia University ^*  (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ACE inhibitors; Amlodipine; Myocardial oxygen consumption; Nitric oxide; Statins

Indexed keywords

AMLODIPINE; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID; N ACETYL S NITROSOPENICILLAMINE; N(G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; OXYGEN; RAMIPRIL; SIMVASTATIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; HEART; MALE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT;

EID: 0033839002     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200036001-00061     Document Type: Article

References (26)

1. Regulation of the mevalonate pathway
2. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease
3. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
4. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study Group (WOSCOPS)
5. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication
6. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase
7. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
8. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
9. Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease
10. Increased apoptosis in the heart of genetic hypertension, associated with increased fibroblasts
11. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
12. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors
13. Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected mechanism of action of a calcium channel-blocking agent
14. Nitric oxide regulates mitochondrial respiration and cell function by inhibiting cytochrome oxidase
15. Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating MVo(2) in normal canine and failing human hearts
16. ACE inhibitors stimulate nitric oxide production to modulate myocardial oxygen consumption
17. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day
18. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats
19. Pharmacodynamics of plasma nitrate/nitrite as an indication of nitric oxide formation in conscious dogs
20. Function and production of nitric oxide in the coronary circulation of the conscious dog during exercise
21. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog
22. Mechanisms of nitrate accumulation in plasma during pacing-induced heart failure in conscious dogs
23. Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption
24. Statins and blockers of the reninangiotensin system: Vascular protection beyond their primary mode of action
25. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis
26. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure